Preclinical studies support this approach; for instance, co-inhibition of immune checkpoints such as PD-1, CTLA-4, and TIM-3 alongside CAR T-cell therapy has demonstrated improved tumor control and prolonged survival in the murine and canine models [132]. This evidence concerns the gene HAVCR2 and neoplasm.